Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Daiichi Sankyo Company has approved the dissolution of its subsidiaries Laboratoire Daiichi Sanofi-Aventis and Sanofi-Aventis Daiichi Pharmaceutical.
Subscribe to our email newsletter
The impact of this dissolution on the earnings of Daiichi Sankyo of the fiscal year ending March 2009 will be negligible, the company said.
Daiichi Sankyo and Sanofi-Aventis have previously established the joint ventures Laboratoire Daiichi Sanofi-Aventis (LDS) and Sanofi-Aventis Daiichi Pharmaceutical (SDC) with the objective of developing pharmaceuticals for treatment of thrombotic disease.
The dissolution of LDS and SDC was agreed upon by both companies in 2005. With post-dissolution procedures now possible, LDS is to be dissolved on January 13, 2009 and SDC is to be dissolved on December 26, 2008.